UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the
month of August, 2008
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No
X
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 14,
2008
is hereby incorporated by reference into the registration statements on Form
F-3
(File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
Ltd. with the Securities and Exchange Commission on March 23, 2007 and October
30, 2007, respectively, and the registration statements on Form S-8 (File No.
333-148058 and File No. 333-148574) filed by XTL Biopharmaceuticals Ltd. with
the Securities and Exchange Commission on December 14, 2007 and January 18,
2008, respectively.
XTL
Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of
Directors
VALLEY
COTTAGE, NEW YORK, August 14, 2008 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that Samuel
H.
Rudman, Esq., has been appointed to XTL's Board of Directors, effective as
of
August 13, 2008.
Mr.
Rudman, 40, is a named partner at a US law firm specializing in complex
litigation, emphasizing securities, consumer, insurance, healthcare, human
rights, employment discrimination and antitrust class actions. Mr. Rudman's
practice is focused primarily on the area of securities and shareholder
litigation, and complex issues of disclosure and corporate governance.
Mr.
Rudman graduated with a BA in political science from Binghamton University
and
with a JD from Brooklyn Law School.
Ron
Bentsur, Chief Executive Officer of XTL, commented “We are excited to have Sam
join our Board of Directors. Sam is well-versed in matters related to corporate
governance. We believe that his skills provide a valuable addition to XTL's
Board, as we prepare for the next stage of the company’s growth following what
we hope will be a successful completion of our Phase 2b study of Bicifadine
in
Q4 2008.”
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of diabetic neuropathic pain and HCV. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
also has an active in-licensing and acquisition program designed to identify
and
acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
-2-
Cautionary
Statement
Some
of the statements included in this press release, particularly those
anticipating future clinical and business prospects for our clinical compound
for neuropathic pain, Bicifadine, growth and operating strategies and similar
matters, may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995. Among the factors that could cause our actual results to
differ materially is our ability to complete in a timely and cost effective
manner clinical trials on Bicifadine, which could directly impact our ability
to
continue to fund our operations; our ability to meet anticipated development
timelines for all of our drug candidates due to recruitment, clinical trial
results, manufacturing capabilities or other factors; our ability to obtain
regulatory approvals for commercial sale of our products; the success of our
drug development and marketing arrangements with third parties; and other risk
factors identified from time to time in our reports filed with the Securities
and Exchange Commission, including our annual report on Form 20-F filed with
the
Securities and Exchange Commission on March 27, 2008. Any forward-looking
statements set forth in this press release speak only as of the date of this
press release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at http://www.xtlbio.com.
The information in our website is not incorporated by reference into this press
release and is included as an inactive textual reference only.
-3-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
||
| |
|
|
|
Date:
August 14, 2008
|
By: | /s/ Bill Kessler |
|
Bill
Kessler
|
||
|
Director
of Finance
|
||
-4-